GlassScriptPhysician profile
Paul Chu
NPI 1851370381
$2,305.51
in general payments reported to CMS, 2019-2025
8 companies · $500 in 2025
The $500 reported for 2025 was more than what 83% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2021: $125 · 2022: $513 · 2023: $228 · 2024: $609 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $480.46 | 2022-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $421.67 | 2023-2024 | Vtama |
| Abbvie INC. | $394.32 | 2019-2022 | |
| Galderma Laboratories, L.P. | $318.93 | 2019-2023 | Aklief, Epsolay, Twyneo |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $249.98 | 2021-2025 | |
| Botanix Sb INC | $125.00 | 2025 | Sofdra |
| Astrazeneca Pharmaceuticals LP | $65.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.